Despite the abundance of P-G3 Lyp1 in plaques using our targeted delivery approach and the improvements found in atherosclerosis outcome with treatment, our study is limited by the phase of disease most relevant for compound efficiency. The gene discussed is PTPN22; the disease is atherosclerosis.